Login / Signup

Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.

Patricia PautierAntoine ItalianoSophie Piperno-NeumannChristine ChevreauNicolas PenelNelly FirminPascaline Boudou-RouquetteFrançois BertucciValérie Lebrun-LyIsabelle Ray-CoquardElsa KalbacherEmmanuelle BompasOlivier CollardNicolas IsambertCécile GuillemetMaria RiosAxel Le CesneCorinne BalleyguierBaptiste ArchambaudFlorence Duffaudnull null
Published in: The New England journal of medicine (2024)
Combination therapy with doxorubicin and trabectedin induction, followed by trabectedin maintenance, was associated with improved overall survival and progression-free survival, as compared with doxorubicin alone, among patients with metastatic or surgically unresectable uterine or soft-tissue leiomyosarcoma. (Funded by PharmaMar and others; LMS04 ClinicalTrials.gov number, NCT02997358.).
Keyphrases
  • free survival
  • combination therapy
  • drug delivery
  • cancer therapy
  • soft tissue
  • locally advanced
  • squamous cell carcinoma
  • rectal cancer